Chimerix (CMRX) AI Stock Analysis

• Market Cap: $797.33M
• Dividend Yield: N/A
• Average Volume (3M): 6.45M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.49
• Revenue Growth: -34.57%
• EPS Growth: -6.31%
• Country: US
• Employees: 79
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 93,803,850
• 10 Day Avg. Volume: 1,548,454
• 30 Day Avg. Volume: 6,446,098
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4807.90
• Price to Cash Flow (P/CF): -9.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.54
• Price Target Upside: 0.35% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5

Chimerix's overall score reflects its mixed financial performance and the positive impact of recent corporate developments. While financial challenges and negative cash flows weigh down the score, strong technical momentum and strategic corporate events, such as the merger with Jazz Pharmaceuticals, provide a promising outlook. However, valuation concerns and ongoing losses suggest caution, with eventual profitability being key to future improvements.

Positive Factors

Acquisition

The acquisition agreement between Chimerix and Jazz Pharmaceuticals is expected to close in a timely manner, offering a stable financial outlook for Chimerix.

Drug Potential

Dordaviprone, the lead drug in phase III trials, is seen as having the potential to become the standard of care with durable revenues into 2037.

Regulatory Approval

The FDA has accepted Chimerix's NDA with priority review status for dordaviprone, indicating a strong potential for approval.

Negative Factors

Cash Burn

The company's estimated cash burn for the fiscal year is $98 million, suggesting a significant outflow of cash.

Financial Performance

Chimerix reported 4Q24 GAAP EPS of ($0.26) and non-GAAP EPS of ($0.25), both slightly below estimates.

Valuation Concerns

The deal's valuation is lower than the biotech average, suggesting some skepticism about the company's prospects.

Chimerix Business Overview & Revenue Model

Company Description

Chimerix, Inc. (CMRX) is a biopharmaceutical company focused on the development and commercialization of novel antiviral therapeutics. Headquartered in Durham, North Carolina, Chimerix is committed to developing medicines that improve outcomes for patients facing serious diseases. The company's core product includes brincidofovir, an antiviral medication that is in development for various indications, including smallpox and other viral infections. Chimerix aims to address significant unmet medical needs with its innovative drug candidates by leveraging proprietary chemical libraries and expertise in antiviral drug development.

How the Company Makes Money

Chimerix generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by advancing its lead product candidates through clinical trials and seeking regulatory approval for commercial use. Upon approval, revenue is generated through the sale of these drugs to healthcare providers, governments, or other entities. Additionally, Chimerix may engage in licensing agreements, collaborations, or partnerships with other pharmaceutical companies that provide upfront, milestone, and royalty payments, contributing to the company's earnings. Their business model also includes potential government contracts, especially for drugs like brincidofovir, which can be stockpiled for biodefense purposes.

Chimerix Financial Statement Overview

Summary

Chimerix faces significant financial challenges, with declining revenues and persistent losses. Despite a strong balance sheet with no debt and positive equity, the negative cash flow and profitability metrics emphasize the need for strategic changes and improved operational efficiency.

Income Statement

Chimerix's financial performance shows a concerning trend with declining revenues and consistent losses. The total revenue dropped significantly from 2022 to 2024, and the company reported negative EBIT and net income for the past several years. The gross profit margin appears positive due to minimal costs, but overall profitability is a significant issue with negative net profit and EBIT margins.

Balance Sheet

The balance sheet presents a mixed picture. Chimerix has a strong equity position with no debt as of the latest year, resulting in a favorable debt-to-equity ratio. However, the return on equity is negative due to consecutive net losses, indicating inefficient use of equity to generate profit. The equity ratio is strong, highlighting a solid capital structure despite operational challenges.

Cash Flow

The cash flow statement reveals substantial negative free cash flow, indicating cash burn issues. Although operating cash flow improved slightly over the years, the company continues to rely on investing and financing activities for liquidity. The negative free cash flow to net income ratio underscores the cash flow challenges and emphasizes the need for operational improvements.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
212.00K	324.00K	33.82M	1.98M	5.37M
	Gross Profit
212.00K	324.00K	33.38M	1.51M	-30.86M
	EBIT
-96.57M	-93.06M	-60.39M	-173.40M	-44.52M
	EBITDA
-96.57M	-92.97M	-60.39M	-90.34M	-44.11M
	Net Income Common Stockholders
-88.39M	-82.09M	172.17M	-255.79M	-42.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
31.05M	182.84M	217.33M	88.37M	78.96M
	Total Assets
146.01M	212.77M	279.34M	100.54M	84.72M
	Total Debt
458.00K	1.30M	2.07M	16.39M	2.81M
	Net Debt
-30.59M	-26.36M	-23.77M	995.00K	-44.17M
	Total Liabilities
24.33M	19.75M	22.48M	32.29M	11.35M
	Stockholders Equity
121.68M	193.03M	256.86M	68.25M	73.38M
Cash Flow		Free Cash Flow
-75.26M	-69.18M	-46.94M	-100.14M	-36.10M
	Operating Cash Flow
-74.98M	-69.09M	-46.87M	-99.93M	-36.04M
	Investing Cash Flow
71.32M	70.60M	70.04M	-44.09M	64.71M
	Financing Cash Flow
7.05M	308.00K	-12.72M	112.43M	1.41M

Chimerix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMRX, the sentiment is Positive. The current price of 8.51 is above the 20-day moving average (MA) of 8.30, above the 50-day MA of 5.93, and above the 200-day MA of 2.45, indicating a bullish trend. The MACD of 0.78 indicates Positive momentum. The RSI at 83.60 is Negative, neither overbought nor oversold. The STOCH value of 57.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CMRX.

Chimerix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	76 Outperform	$396.47M	6.74	28.70%	10.81%	-0.86%	-13.33%
SRPT	68 Neutral	$6.83B	29.54	19.71%	―	52.97%	―
CMRX	62 Neutral	$797.33M	―	-56.17%	―	-34.57%	-6.31%
BCRX	52 Neutral	$1.64B	―	18.68%	―	36.00%	63.50%
VIR	51 Neutral	$918.86M	―	-38.09%	―	-13.90%	16.56%
AKBA	49 Neutral	$498.95M	―	91.25%	―	-17.75%	-19.17%
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%

Chimerix Corporate Events

Chimerix Merges with Jazz Pharmaceuticals in $935M Deal

On March 4, 2025, Chimerix entered into a merger agreement with Jazz Pharmaceuticals, under which Jazz will acquire Chimerix for $8.55 per share, totaling approximately $935 million. This acquisition, expected to close in the second quarter of 2025, will allow Jazz to expand its oncology portfolio with dordaviprone, a treatment for H3 K27M-mutant diffuse glioma, which has no FDA-approved therapies. The transaction is anticipated to provide Jazz with a near-term commercial opportunity and strengthen its presence in the rare oncology space, while Chimerix shareholders are recommended to tender their shares.